[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transthyretin-amyloidosis-with-cardiomyopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transthyretin-amyloidosis-with-cardiomyopathy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,86],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100642140","long-term-safety-of-eplontersen-treated-attr-patients-and-in-liver-transplant-and-severely-hepatic-impaired-subpopulations-100642140",false,"NCT07654855","Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulations","Post-Authorisation Safety Study: A Cohort Event Monitoring Study to Characterise the Use of Eplontersen in Patients With Prior Liver Transplant and Pre-existing Severe Hepatic Impairment and to Assess Long-term Safety Among All New Users of Eplontersen (sTTRing)","sTTRing","Inclusion Criteria:\n\n1. D8450R00003 participants who consented to have their data used for future related research studies.\n2. D8450R00003 participants who initiated eplontersen treatment up to 1-year prior to enrolment into D8450R00003 study observation period, irrespective of ATTR phenotype or genotype. For the comparative analyses, patients unexposed to eplontersen treatment and who initiated another ATTR treatment during D8450R00003 study observation period will be included\n\nExclusion Criteria:\n\n1. Patients with exposure to eplontersen more than 1-year prior to enrolment into D8450R00003 study.\n2. Patients who participated in an interventional ATTR study in the 12-months prior to enrolment into D8450R00003 study.","ALL","18 Years",{"count":20,"type":21},320,"ESTIMATED","OBSERVATIONAL","The aim of this observational cohort study is to characterise use of eplontersen in patients with prior liver transplant or with pre-existing severe hepatic impairment, as well as to assess long-term safety among all new users of eplontersen; all are areas of missing information\n\nPrimary objectives are:\n\n1. To describe demographic and clinical characteristics of patients at eplontersen initiation, including the prevalence of prior liver transplant (overall and by reason for liver transplant), and the prevalence of severe hepatic impairment; and to describe patients in these subgroups (prior liver transplant, severe hepatic impairment).\n2. To describe long-term safety in patients who initiate eplontersen treatment, including onset of new clinical events, abnormal laboratory values and serious adverse events.",[25,26,27],"Transthyretin Amyloidosis","Transthyretin Amyloidosis With Cardiomyopathy","Transthyretin Amyloidosis With Polyneuropathy",[29],"ATTR, Transthyretin amyloidosis","NOT_YET_RECRUITING","2026-06-11",{"date":33,"type":34},"2026-06-17","ACTUAL",{"date":36,"type":21},"2026-09-01",{"date":38,"type":21},"2032-01-29",{"name":40,"class":41},"AstraZeneca","INDUSTRY",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100597009","phase-3-triton-cm-a-study-to-evaluate-nucresiran-in-patients-with-transthyretin-amyloidosis-with-cardiomyopathy-100597009","NCT07052903","TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy","TRITON-CM: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Transthyretin-Mediated Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)","Inclusion Criteria\n\n* Has documented diagnosis of ATTR amyloidosis with cardiomyopathy including those with hereditary ATTR (hATTR) or wild-type ATTR (wATTR) amyloidosis.\n* Has medical history of heart failure (HF) with at least 1 prior hospitalization for HF or signs and symptoms that require treatment with a diuretic.\n* Has screening N-terminal prohormone B-type natriuretic peptide (NT-proBNP) \\>300 ng\u002FL and \\\u003C8500 ng\u002FL; In patients with permanent or persistent atrial fibrillation, screening NT-proBNP \\>600 ng\u002FL and \\\u003C8500 ng\u002FL.\n* Patients may be receiving approved TTR stabilizers for ATTR amyloidosis (eg, tafamidis, acoramidis) and may be receiving background therapy for HF at the discretion of the Investigator.\n\nExclusion Criteria\n\n* Has New York Heart Association (NYHA) Class IV HF; or NYHA Class III heart failure AND ATTR Amyloidosis Disease Stage 3.\n* Has a polyneuropathy disability (PND) Score IIIa, IIIb, or IV.\n* Has an estimated glomerular filtration rate eGFR of \\\u003C30 mL\u002Fmin\u002F1.73m\\^2 at screening.\n* Has received prior or currently receiving TTR-lowering therapy","85 Years",{"count":51,"type":21},1250,"INTERVENTIONAL",[54],"PHASE3","The purpose of this study is to:\n\n* Evaluate the efficacy of nucresiran compared to placebo on reducing all-cause mortality and cardiovascular (CV) events\n* Evaluate the efficacy of nucresiran compared to placebo on additional assessments of CV events and\u002For death\n* Evaluate the efficacy of nucresiran compared to placebo on patient-reported health status and health-related quality of life",[26],[58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74],"ATTR-CM","ATTR amyloidosis with cardiomyopathy","ATTR","Heriditary ATTR","hATTR","Wild-type ATTR","wATTR","Cardiomyopathy","Amyloidosis","TTR","Transthyretin","TTR-mediated amyloidosis","RNAi","RNAi therapeutic","TTR cardiomyopathy","V122i","TTR amyloidosis","RECRUITING","2026-06-10",{"date":78,"type":34},"2026-06-12",{"date":80,"type":34},"2025-07-02",{"date":82,"type":21},"2032-11-30",{"name":84,"class":41},"Alnylam Pharmaceuticals",233,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":96,"conditions":97,"keywords":98,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},"100620473","demonsttrate-a-global-observational-multicenter-long-term-study-of-patients-with-attr-cm-in-a-real-world-setting-100620473","NCT07358078","DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting","DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With Transthyretin-Mediated Amyloidosis With Cardiomyopathy in a Real-World Setting","DemonsTTRate","Inclusion Criteria:\n\n* Has a diagnosis of ATTR-CM\n* Is initiating treatment with vutrisiran or another approved ATTR-CM therapy\n\nExclusion Criteria:\n\n* Is enrolled in an interventional clinical trial",{"count":95,"type":21},2000,"The purpose of this study is to:\n\n* Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) treated with vutrisiran in routine clinical care\n* Describe treatment patterns of adult patients with ATTR-CM treated with vutrisiran in routine clinical care\n* Assess health-related quality of life (HRQOL) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care\n* Assess healthcare resource use (HCRU) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care Compare the long-term effectiveness of vutrisiran versus other approved ATTR-CM treatments in routine clinical care",[26],[58,68,66,60,65],"2026-04-23",{"date":101,"type":34},"2026-04-24",{"date":103,"type":34},"2026-01-09",{"date":105,"type":21},"2030-10-23",{"name":84,"class":41},4]